e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 14, 2008
ADVENTRX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
Delaware
(State or Other Jurisdiction of
Incorporation)
|
|
001-32157
(Commission File No.)
|
|
84-1318182
(IRS Employer Identification No.) |
6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
(Address of Principal Executive Offices and Zip Code)
N/A
(Former name or former address if changed since last report)
Registrant’s telephone number, including area code: (858) 552-0866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TABLE OF CONTENTS
On January 14, 2008, ADVENTRX Pharmaceuticals, Inc. (“ADVENTRX”) updated aspects of its corporate
presentation as reflected in the slides attached as Exhibit 99.1 to this Current Report on Form 8-K
(the “Report”), which slides are incorporated herein by reference. Evan M. Levine, Chief Executive
Officer of ADVENTRX, and other ADVENTRX executives will present the information reflected in the
slides attached as Exhibit 99.1 to this Report commencing January 14, 2008 at various investor and
analyst meetings.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits. |
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Index to
Exhibits filed with this report.
Forward Looking Statements
ADVENTRX cautions you that statements information included in the slides attached hereto as Exhibit
99.1 that are not a description of historical facts are forward-looking statements that involve
risks and assumptions that, if they materialize or do not prove to be accurate, could cause
ADVENTRX’s results to differ materially from historical results or those expressed or implied by
such forward-looking statements. These risks and uncertainties include, but are not limited to:
the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to
meet its anticipated or stated goals and milestones; the risk that preclinical results are not
indicative of the success of subsequent clinical trials and the results of pending clinical trials;
the risk the FDA determines ADVENTRX’s product candidates are not bioequivalent to the applicable
reference product; difficulties or delays in manufacturing, marketing and obtaining regulatory
approval for ADVENTRX’s product candidates; the potential for regulatory authorities to require
additional preclinical work or other clinical requirements to support regulatory filings; the scope
and validity of patent protection for ADVENTRX’s product candidates; patent and non-patent
exclusivity covering Navelbine® and Taxotere®; and other risks and uncertainties more fully
described in ADVENTRX’s press releases and periodic filings with the Securities and Exchange
Commission. ADVENTRX’s public filings with the Securities and Exchange Commission are available at
http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date when made. ADVENTRX does not intend to update any forward-looking statement included
in the slides attached hereto as Exhibit 99.1 to reflect events or circumstances arising after the
date on which it was made. This caution is made under the safe harbor provisions of Section 21E of
the Securities Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
|
|
|
|
| |
ADVENTRX Pharmaceuticals, Inc.
|
|
| Dated: January 14, 2008 |
By: |
/s/ Evan M. Levine
|
|
| |
|
Name: |
Evan M. Levine |
|
| |
|
Title: |
Chief Executive Officer |
|
| |